Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Xenon Pharmaceuticals Inc. is currently navigating 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners, meaning each examiner is currently handling a single matter for the company. The portfolio is spread across 4 distinct art units, which indicates that the filings cover various specialized technical niches within the pharmaceutical field. SOROUSH, LAYLA is identified as the busiest examiner, responsible for 1 pending office action.
With multiple distinct examiners involved, the prosecution team must adapt to different sets of examiner preferences and styles. The presence of 4 distinct art units suggests that the legal strategy must address the specific standards of several examining groups. Because there are pending office actions and no overlap in personnel across these specific cases, insights gained from one examiner may not apply to others. Practitioners should be prepared for the requirements across the 4 distinct art units currently in play. SOROUSH, LAYLA represents one of the individual points of contact for this portfolio.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §102 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| CARCANAGUE, DANIEL R | 1 | 80.8% | +24.5% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746981 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | CARCANAGUE, DANIEL R | 196d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330100 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746981 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | CARCANAGUE, DANIEL R | 196d overdue |
| 18415139 | METHODS FOR TREATING PAIN | SZNAIDMAN, MARCOS L | 19d overdue |
| 18330100 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | 13d |
| 19094303 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | SOROUSH, LAYLA | 14d |
| 18603554 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | HUTTER, GILLIAN A | 46d |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1622 | 1 |
| 1621 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19094303 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | SOROUSH, LAYLA | 1622 | §103DP | Final Rejection | 14d | Pending | Mar 28, 2025 |
| 18746981 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | CARCANAGUE, DANIEL R | 1621 | §102Other | Non-Final OA | 196d overdue | Pending | Jun 18, 2024 |
| 18603554 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | HUTTER, GILLIAN A | 1625 | §103 | Final Rejection | 46d | Pending | Mar 13, 2024 |
| 18415139 | METHODS FOR TREATING PAIN | SZNAIDMAN, MARCOS L | 1628 | §103 | Final Rejection | 19d overdue | Pending | Jan 17, 2024 |
| 18330100 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | 1628 | §102§103§112 | Final Rejection | 13d | Pending | Jun 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial